144 related articles for article (PubMed ID: 35967575)
41. Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.
Cavé H; Caye A; Ghedira N; Capri Y; Pouvreau N; Fillot N; Trimouille A; Vignal C; Fenneteau O; Alembik Y; Alessandri JL; Blanchet P; Boute O; Bouvagnet P; David A; Dieux Coeslier A; Doray B; Dulac O; Drouin-Garraud V; Gérard M; Héron D; Isidor B; Lacombe D; Lyonnet S; Perrin L; Rio M; Roume J; Sauvion S; Toutain A; Vincent-Delorme C; Willems M; Baumann C; Verloes A
Eur J Hum Genet; 2016 Aug; 24(8):1124-31. PubMed ID: 26757980
[TBL] [Abstract][Full Text] [Related]
42. Pathogenic CARD11 mutations affect B cell development and differentiation through a noncanonical pathway.
Wei Z; Zhang Y; Chen J; Hu Y; Jia P; Wang X; Zhao Q; Deng Y; Li N; Zang Y; Qin J; Wang X; Lu W
Sci Immunol; 2019 Nov; 4(41):. PubMed ID: 31784498
[TBL] [Abstract][Full Text] [Related]
43. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
[TBL] [Abstract][Full Text] [Related]
44. Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL.
Gagne AL; Maguire JA; Gandre-Babbe S; Chou ST; Tasian SK; Loh ML; Weiss MJ; Gadue P; French DL
Stem Cell Res; 2018 Aug; 31():157-160. PubMed ID: 30096712
[TBL] [Abstract][Full Text] [Related]
45. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.
Martínez-Feito A; Melero J; Mora-Díaz S; Rodríguez-Vigil C; Elduayen R; González-Granado LI; Pérez-Méndez D; Sánchez-Zapardiel E; Ruiz-García R; Menchén M; Díaz-Madroñero J; Paz-Artal E; Del Orbe-Barreto R; Riñón M; Allende LM
Immunobiology; 2016 Jan; 221(1):40-7. PubMed ID: 26323380
[TBL] [Abstract][Full Text] [Related]
46. Cutaneous involvement in an 8-year-old boy with Ras-associated autoimmune leucoproliferative disorder (RALD).
Giacaman A; Bauzá Alonso A; Salinas Sanz JA; Dapena Díaz JL; Ramos Asensio R; Ferrés Ramis L; Durán Pastor MA; Martín-Santiago A
Clin Exp Dermatol; 2018 Dec; 43(8):913-916. PubMed ID: 29908030
[TBL] [Abstract][Full Text] [Related]
47. JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.
Calvo KR; Price S; Braylan RC; Oliveira JB; Lenardo M; Fleisher TA; Rao VK
Blood; 2015 Apr; 125(18):2753-8. PubMed ID: 25691160
[TBL] [Abstract][Full Text] [Related]
48. Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome.
Mason-Suares H; Toledo D; Gekas J; Lafferty KA; Meeks N; Pacheco MC; Sharpe D; Mullen TE; Lebo MS
Eur J Hum Genet; 2017 Apr; 25(4):509-511. PubMed ID: 28098151
[TBL] [Abstract][Full Text] [Related]
49. [Multiple granular cell tumours in a patient with Noonan's syndrome and juvenile myelomonocytic leukaemia].
Castagna J; Clerc J; Dupond AS; Laresche C
Ann Dermatol Venereol; 2017 Nov; 144(11):705-711. PubMed ID: 28728859
[TBL] [Abstract][Full Text] [Related]
50. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
Loh ML; Sakai DS; Flotho C; Kang M; Fliegauf M; Archambeault S; Mullighan CG; Chen L; Bergstraesser E; Bueso-Ramos CE; Emanuel PD; Hasle H; Issa JP; van den Heuvel-Eibrink MM; Locatelli F; Stary J; Trebo M; Wlodarski M; Zecca M; Shannon KM; Niemeyer CM
Blood; 2009 Aug; 114(9):1859-63. PubMed ID: 19571318
[TBL] [Abstract][Full Text] [Related]
51. Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
Pearson S; Guo B; Pierce A; Azadbakht N; Brazzatti JA; Patassini S; Mulero-Navarro S; Meyer S; Flotho C; Gelb BD; Whetton AD
J Proteome Res; 2020 Jan; 19(1):194-203. PubMed ID: 31657576
[TBL] [Abstract][Full Text] [Related]
52. Clinical, immunological, and genetic features in 780 patients with autoimmune lymphoproliferative syndrome (ALPS) and ALPS-like diseases: A systematic review.
Hafezi N; Zaki-Dizaji M; Nirouei M; Asadi G; Sharifinejad N; Jamee M; Erfan Rasouli S; Hamedifar H; Sabzevari A; Chavoshzadeh Z; Yazdani R; Abolhassani H; Aghamohammadi A; Azizi G
Pediatr Allergy Immunol; 2021 Oct; 32(7):1519-1532. PubMed ID: 33963613
[TBL] [Abstract][Full Text] [Related]
53. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
[TBL] [Abstract][Full Text] [Related]
54. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
[TBL] [Abstract][Full Text] [Related]
55. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
[TBL] [Abstract][Full Text] [Related]
56. Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway.
Bunda S; Qin K; Kommaraju K; Heir P; Ohh M
Oncogene; 2015 Feb; 34(6):789-97. PubMed ID: 24469048
[TBL] [Abstract][Full Text] [Related]
57. Primary Graft Failure but Treatment Success: A Case of Reversion to Heterozygosity After Allogeneic Hematopoietic Cell Transplantation With Autologous Hematopoietic Recovery in a Child With CBL-related Juvenile Myelomonocytic Leukemia.
Oshrine B
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e426-e428. PubMed ID: 32032248
[TBL] [Abstract][Full Text] [Related]
58. Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome.
Takagi M; Ogata S; Ueno H; Yoshida K; Yeh T; Hoshino A; Piao J; Yamashita M; Nanya M; Okano T; Kajiwara M; Kanegane H; Muramatsu H; Okuno Y; Shiraishi Y; Chiba K; Tanaka H; Bando Y; Kato M; Hayashi Y; Miyano S; Imai K; Ogawa S; Kojima S; Morio T
J Allergy Clin Immunol; 2017 Jun; 139(6):1914-1922. PubMed ID: 27845235
[TBL] [Abstract][Full Text] [Related]
59. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
[TBL] [Abstract][Full Text] [Related]
60. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
